Literature DB >> 12452738

Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Yie W Chien1, Senshang Lin.   

Abstract

A number of programmable rate-controlled drug delivery technologies have been developed during the last two decades with the aim of regulating the rate of drug delivery, sustaining the duration of therapeutic action and/or targeting the delivery of drug to a specific tissue. As a result, several therapeutically beneficial outcomes can be achieved, such as: (i) controlled delivery of a therapeutic dose at a desirable rate of delivery; (ii) maintenance of drug concentrations within an optimal therapeutic range for prolonged duration of treatment; (iii) maximisation of efficacy-dose relationship; (iv) reduction of adverse effects; (v) minimisation of the need for frequent dose intake; and (vi) enhancement of patient compliance. The treatment of illness can thus be optimised. To gain a better understanding of how to optimise the treatment of illnesses by applying programmable rate-controlled drug delivery technologies, this article reviews the scientific concepts and technical principles behind the development of various programmable rate-controlled drug delivery systems that have been marketed or are under active development. Finally, the roles of these technologies in optimising therapeutic outcomes in nine therapeutic areas are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12452738     DOI: 10.2165/00003088-200241150-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  194 in total

Review 1.  Injectable and implantable contraceptives.

Authors:  V E Cullins
Journal:  Curr Opin Obstet Gynecol       Date:  1992-08       Impact factor: 1.927

2.  Transdermal delivery of testosterone with Testoderm to provide a normal circadian pattern of testosterone.

Authors:  V A Place; K C Nichols
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

Review 3.  Drug delivery by phonophoresis.

Authors:  P Tyle; P Agrawala
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

4.  Plasma levels of d-norgestrel after oral administration.

Authors:  E Weiner; A Victor; E D Johansson
Journal:  Contraception       Date:  1976-11       Impact factor: 3.375

Review 5.  Electrically-assisted transdermal drug delivery.

Authors:  J E Riviere; M C Heit
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

6.  Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group.

Authors:  A O Turkes; W B Peeling; K Griffiths
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

Review 7.  Current approaches to the management of cancer pain: a review.

Authors:  N I Cherny; K M Foley
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

8.  Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.

Authors:  C A Stuenkel; R E Dudley; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1991-05       Impact factor: 5.958

Review 9.  Intrauterine steroid contraceptives.

Authors:  P C Scholten; G C Christaens; A A Haspels
Journal:  Wien Med Wochenschr       Date:  1987-11-15

10.  Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group.

Authors:  S B Fiel; H J Fuchs; C Johnson; I Gonda; A R Clark
Journal:  Chest       Date:  1995-07       Impact factor: 9.410

View more
  7 in total

1.  New cyclodextrin hydrogels cross-linked with diglycidylethers with a high drug loading and controlled release ability.

Authors:  Carmen Rodriguez-Tenreiro; Carmen Alvarez-Lorenzo; Ana Rodriguez-Perez; Angel Concheiro; Juan J Torres-Labandeira
Journal:  Pharm Res       Date:  2006-12-07       Impact factor: 4.200

Review 2.  Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.

Authors:  Agnes L F Chan; Yie W Chien; Shun Jin Lin
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings.

Authors:  Todd J Johnson; Priya Srinivasan; Theodore H Albright; Karen Watson-Buckheit; Lorna Rabe; Amy Martin; Chou-Pong Pau; R Michael Hendry; Ron Otten; Janet McNicholl; Robert Buckheit; James Smith; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

4.  In vitro biocompatibility of thermally gelling liquid mucoadhesive loaded curcuminoids in colorectal cancer chemoprevention.

Authors:  Ming-Jenn Chen; Ya-Min Cheng; Pei-Heng Lai; June-Fu Wu; Yi-Chiang Hsu
Journal:  Int J Colorectal Dis       Date:  2012-01-07       Impact factor: 2.571

Review 5.  Molecularly imprinted polymers: present and future prospective.

Authors:  Giuseppe Vasapollo; Roberta Del Sole; Lucia Mergola; Maria Rosaria Lazzoi; Anna Scardino; Sonia Scorrano; Giuseppe Mele
Journal:  Int J Mol Sci       Date:  2011-09-14       Impact factor: 5.923

6.  Iontophoretic and microneedle mediated transdermal delivery of glycopyrrolate.

Authors:  Meera Gujjar; Ajay K Banga
Journal:  Pharmaceutics       Date:  2014-12-22       Impact factor: 6.321

Review 7.  Stimuli Responsive, Programmable DNA Nanodevices for Biomedical Applications.

Authors:  Udisha Singh; Vinod Morya; Bhaskar Datta; Chinmay Ghoroi; Dhiraj Bhatia
Journal:  Front Chem       Date:  2021-06-30       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.